ERBB2 and breast cancer: The Choosing Wisely campaign and the National Comprehensive Cancer Network (NCCN) version 6.2024 guidelines recommend against sentinel lymph node biopsies in women over 70 with early-stage, hormone receptor (HR)-positive, Herceptin receptor 2 (HER2)-negative breast cancers [21].